Q1 2026 Results: $7.3M ATM Offering Extends Cash Runway to Q3 2027 Amidst Clinical Progress
ACRV sits 89% above its 52-week low of $1.05 on light trading volume (0.2× avg).
Summary
Acrivon Therapeutics reported Q1 2026 financial results, including a $19.0 million net loss, and announced a $7.3 million ATM offering in April 2026 that extends its cash runway into Q3 2027.
Key Events · Earnings and Guidance · ACRV
-
Q1 2026 Financial Results
The company reported a net loss of $19.0 million for the three months ended March 31, 2026, a slight improvement from a $19.7 million net loss in the prior year period.
-
Cash Runway Extended to Q3 2027
Existing cash, cash equivalents, and investments of $97.7 million as of March 31, 2026, combined with $7.3 million from a subsequent ATM offering, are expected to fund operations into the third quarter of 2027.
-
April 2026 ATM Offering Completed
The company issued and sold 4,054,954 shares of common stock at $1.80 per share in April 2026, generating net proceeds of $7.3 million. This represents approximately 10.5% dilution based on shares outstanding at March 31, 2026.
-
Positive Clinical Pipeline Updates
Acrivon reiterated positive clinical data for ACR-368 in endometrial cancer (52% cORR in serous EC) and ACR-2316 in small cell lung cancer (SCLC) and squamous non-small cell lung cancer (NSCLC), with both programs advancing.
Analysis · ACRV · Life Sciences
This quarterly report provides an update on Acrivon Therapeutics' financial health and clinical pipeline. The $7.3 million capital raise through an At-The-Market (ATM) offering, while dilutive, is a critical financing event that extends the company's operational runway into Q3 2027. This provides necessary funding for ongoing clinical trials for ACR-368 and ACR-2316, which continue to show positive data, and the advancement of new candidates like ACR-6840. The strategic move to bring diagnostic testing in-house also strengthens its precision medicine platform.
At the time of this filing, ACRV was trading at $1.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $74.4M. The 52-week trading range was $1.05 to $3.56. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.